A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Hepatitis C, Chronic
About this trial
This is an interventional treatment trial for Hepatitis C, Chronic focused on measuring Hepatitis C, HCV, Rapid Virologic Response, Sustained Virologic Response, Direct Acting Antiviral, Combination Therapy, HCV RNA, Polymerase inhibitor, Protease inhibitor, Treatment naïve, GS-9190, GS-9451
Eligibility Criteria
Inclusion Criteria:
- Adult subjects 18 to 70 years of age
- Chronic HCV infection for at least 6 months prior to Baseline (Day 1)
- Liver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis
- Monoinfection with HCV genotype 1a or 1b
- HCV treatment-naïve
- Body mass index (BMI) between 18 and 36 kg/m2
- Creatinine clearance ≥ 50 mL/min
- Subject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.
- Screening laboratory values within defined thresholds for alanine aminotransferase (ALT), aspartate aminotransferase (AST), leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium
Exclusion Criteria:
- Autoimmune disease
- Decompensated liver disease or cirrhosis
- Poorly controlled diabetes mellitus
- Severe psychiatric illness
- Severe chronic obstructive pulmonary disease (COPD)
- Serological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype
- Suspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)
- History of hemoglobinopathy
- Known retinal disease
- Subjects who are immunosuppressed
- Subjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse
- Subjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study
- Subjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening
Sites / Locations
- Digestive Health Specialists of the Southeast
- Alabama Liver and Digestive Specialists
- Mayo Clinic
- University of Arizona
- Pacific Oaks Medical Group
- eStudySite
- Scripps Clinic
- eStudySite
- Cedars-Sinai Medical Center
- Synergy Clinical Research Center
- eStudySite
- RESEARCH and EDUCATION, INC
- Medical Associates Research Group
- Kaiser Permanente
- California Pacific Medical Center
- San Francisco Veterans Affairs Medical Center
- University of Colorado Denver
- South Denver Gastroenterology
- Washington Hospital Center
- Bach and Godofsky Infectious Diseases
- Avail Clinical Research, LLC
- University of Florida
- Palmetto Research
- University of Miami
- Scientific Clinical Research, Inc c/o Segal Institute for Clinical Research
- Orlando Immunology Center
- Florida Hospital
- South Florida Center of Gastroenterology, LLC
- Atlanta Gastroenterology Associates
- Emory University, Infectious Disease Clinic
- Liver Center of Atlanta
- Dekalb Gastroenterology
- Infectious Disease Specialists of Atlanta
- Northwestern Memorial Hospital
- University of Chicago
- Indiana University
- IGRF
- Graves Gilbert Clinic
- University of Louisville
- Gastroenterology Associates, LLC
- Digestive Disease Associates, PA
- Johns Hopkins University
- Massachusetts General Hospital
- Beth Israel Deaconess Medical Center
- Partners in Internal Medicine, P.C.
- Henry Ford Health System-Columbus center
- MN Gastroenterology, P.A.
- Gastrointestinal Associates, PA
- Digestive Health Specialists, PA
- Saint Louis University
- Comprehensive Clinical Research
- ID Care 105
- Atlantic Research Affiliates, LLC
- University of Medicine and Dentistry of New Jersey
- UNM Health Sciences Center
- Binghamton Gastroenterology
- North Shore University Hospital
- Concorde Medical Group
- NYU Hepatology Associates
- Cornell University Gastroenterology & Hepatology
- Mount Sinai Medical Center
- Columbia University Medical Center
- Asheville Gastroenterology Associates, P.A.
- Duke University Medical Center
- Consultants for Clinical
- University of Cincinnati
- University Hospitals Case Medical Center
- Options Health Research, LLC
- Albert Einstein Medical Center
- Memphis Gastroenterology Group
- James H. Quillen VA Medical Center
- Columbia Medical Group, The Frist Clinic
- The North Texas Research Institute
- UT Southwestern Medical Center at Dallas
- Kelsey Research Foundation
- Advanced Liver Therapies
- Research Specialists of Texas
- Amcare Research Inc.
- Alamo Medical Research
- Brooke Army Medical Center
- Metropolitan Research
- Liver Institute of Virginia, Bon Secours
- Digestive and Liver Disease Specialists
- Virginia Mason Medical Center, Digestive Disease Institute
- University of Wisconsin Hospital & Clinics
- Landeskrankenhaus Graz West
- Medizinische Universität Graz
- LKH Innsbruck
- Krankenhaus der Elisabethinen Linz GmbH
- AKH der Stadt Wien
- Wilhelminenspital der Stadt Wien
- Ziekenhuis Netwerk Antwerpen
- ULB Erasme
- UCL Saint Luc
- UZ Antwerp
- Centre Hospitalier Universitaire Sart Tilman Liège
- Beaujon Hospital
- Henri Mondor Hospital
- Hôpital de la Croix Rousse
- Saint Joseph Hospital
- Hôpital de I´Archet 2, Service Hépatologie
- Centre Hospitalier Régional d'Orléans, Hôpital de la Source
- Hôpital Cochin
- Groupe Hospitalier du Haut Leveque
- Centre Hospitalier Universitaire de Strasbourg - Hôpital Civil
- Nancy University Hospital Center
- Charite University Medicine
- Leber- und Studienzentrum am Checkpoint
- University Hospital Bonn
- University Hospital Essen
- Klinikum der Johann Wolfgang Goethe-Universität
- University Hospital Freiburg
- Asklepios Klinik Sankt Georg
- Medizinische Hochschule Hannover
- University hospital Heidelberg
- University Hospital Leipzig
- Johannes Gutenberg University Hospital
- Academisch Medisch Centrum Universiteit Van Amsterdam
- Radaboud University Nijmegen Medical Centre (UMC St Radboud)
- Erasmus University Medical Center Rotterdam
- Universitair Medisch Centrum Utrecht
- Wojewodzki Szpital Specjalistyczny im. K. Dluskiego Oddzial Obserwacyjno-Zakazny
- Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza Oddział Obserwacyjno-Zakazny
- Szpital Specjalistyczny w Chorzowie
- Niepubliczny Zakład Opieki Zdrowotnej "Pol-SaNa-Med" Sp. z o.o.
- Wojewodzki Szpital Zespolony w Kielcach
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
- Wojewodzki Specjalistyczny Szpital im. Dr Wl. Bieganskiego w Lodzi
- Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
- Radomski Szpital Specjalistyczny im. Dr Tytusa Chalubinskiego Oddzial obserwacyjno-zakazny z odcinkiem jednego dnia leczenia chorob watroby
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Wojewodzki Szpital Zakazny Oddzial Dzienny
- Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie
- Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego
- Queen Elizabeth Hospital
- Royal Liverpool University Hospital
- Barts and The London Hospital
- Royal Free Hospital
- Kings College Hospital
- Chelsea and Westminster Hospital
- Saint Mary's Hosptial
- Manchester Royal Infirmary
- North Manchester General Hospital
- Nottingham University Hospitals NHS Trust
- Derriford Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Arm 1
Arm 2
Arm 3
GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration